🔴 Problem Identified
European venture capital has shifted from funding high-risk, innovative startups to favoring safer, revenue-proven businesses with predictable returns, resembling small-cap private equity. This risk aversion has created a gap in financing breakthrough technologies emerging from academic research, limiting Europe's potential for radical innovation.
💡 Proposed Solution
Launch a digital investment platform aggregating patient capital from family offices, foundations, sovereign wealth funds, and public sector sources to fund early-stage, high-risk deep tech startups and university spinouts. The platform offers specialized fund structures with extended time horizons (15-20 years), expert-led evaluation panels, and risk-tolerant syndicates, bridging academia and commercialization.
Market Size
Niche
Difficulty
High
Time to MVP
6+ months
Investment
High
Unlock Full Analysis
Get competitor analysis, cost breakdowns, implementation roadmaps, and AI-powered next steps.
Create Free AccountAlready have an account? Log in
Quick Overview
Target Audience
Deep tech startups, university spinouts, academic entrepreneurs, family offices, public sector funds, mission-driven investors
Revenue Potential
€3M - €30M
Competition
Medium
Key Advantage
Niche focus on patient, high-risk deep tech; bridges academic research and commercialization; longer time horizon and ex...